Smad4»ùÒò,Smad4 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Á÷ʽϸ°ûѧ,flow cytometryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö±³¦È«ÏµÄ¤ÇгýÊõ,total mesorectal excisionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÎÄÏ׻عË,literature reviewÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ʳ¹ÜÖ×Áö/ÖÎÁÆ,esophageal neoplasms/therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö±³¦Ö×Áö/·ÅÉäÁÆ·¨,Rectal neoplasms/radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍÁÈÀÉú̬»·¾³,soil ecological environmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 賦µÀ¼äÖÊÁö,gastrointestinal stromal tumorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ԭλRT-PCR,in situ RT-PCRÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ëõ϶¯Âö,inferior phrenic arteryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾Ö²¿ÇгýÊõ,Local resectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾Ö²¿Çгý,Local resectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±ßԵȺ,Side PopulationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Áö˨,tumor thrombusÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« øϸ°û»¯Ñ§,enzyme cytochemistryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« cDNA»ùÒòоƬ,cDNA microarrayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ë¿°±ËáÄÚëÄøÀà,serine endopeptidasesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼¡×éÖ¯,muscle tissueÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÇøÓò»¯ÁÆ,Regional chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃɹÅɳÍÁÊó,Mongolian gerbilÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûÍâ»ùÖʵ°°×ÖÊÀà,extracellular matrix proteinsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ë«ÖØÈ¾É«,double stainingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈýÒ¶Òò×Ó3,Trefoil factor 3Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« µâȾɫ,iodine stainingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ѫ¹ÜÄÚÆ¤Ï¸°ûÉú³¤Òò×Ó-C,Vascular endothelial growth factor-CÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁòË᳤´ºÐ¼î,vincristine sulfateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Óγ̼ìÑé,Runs testÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °×µ°°×ÄÉÃ×Á£,albumin nanoparticlesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒÖÖÆÏû¼õÔÓ½»¼¼Êõ,Suppression subtractive hybridizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Íâ¿ÆÇгý,surgical resectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸Î°©Ç°²¡±ä,precancerous lesion of liverÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Raf¼¤Ã¸ÒÖÖÆµ°°×,Raf kinase inhibitor proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« COX-2µ°°×,COX-2 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö½øÕ¹,tumor progressionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« B7-1»ùÒò,B7-1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÏËά×é֯ϸ°ûÁö,fibrous histiocytomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« HT-29ϸ°ûϵ,HT-29 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÚÆ¤Ï¸°ûÌØÒìÐÔ·Ö×Ó-1,Endothelial cell specific molecule-1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½áºÏ»îÐÔ,Binding activityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûÒÅ´«Ñ§·ÖÎö,cytogenetic analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶¯Âö»¯ÁÆ,intra-arterial chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÐγɹý³Ì,Neoplastic processesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö±³¦Ö×Áö/²¡Àíѧ,rectal neoplasms/pathologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ѫ¹ÜÄÚÆ¤Ï¸°ûÉú³¤Òò×ÓÊÜÌå-3,Vascular endothelial growth factor receptor-3Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ̼ÏËά°å,CFRP plateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÆÏÌÑÇò¾ú³¦¶¾ËØ,staphylococcal enterotoxinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ËáÐÔ»·¾³,acid environmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶þÏ©±û»ù¶þÁò»¯Îï,diallyl disulfideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »Æ²è,yellow teaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÚ·ÖÃÚÏÙÖ×Áö,Endocrine Gland NeoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö΢Ѫ¹ÜÃܶÈ,Microvessel densityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ʳ¹Ü´²,Esophageal bedÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« HMGB1µ°°×,HMGB1 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸Î×ªÒÆ°©,Hepatic metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×éÖ¯½ðÊôµ°°×øÒÖÖÆ¼Á,tissue inhibitor of metalloproteinaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×ÜÉú´æÆÚ,Overall survivalÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐØ¶Îʳ¹Ü°©,thoracic esophageal carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾­µ¼¹Ü¶¯Âö˨ÈûÊõ,Transcatheter arterial embolizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾­µ¼¹Ü¶¯Âö»¯ÁÆË¨ÈûÊõ,transcatheter arterial chemoembolizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« S-ÏÙÜÕ¼×Áò°±ËáÍÑôÈø,S-adenosylmethionine decarboxylaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½á³¦Ö±³¦°©,colorectal carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« DNAÐÞ¸´Ã¸Àà,DNA repair enzymesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶àÌÇÁòËáõ¥,polysaccharide sulfateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿Ë¡ÐÔ·ÖÎö,clonality analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûÖÜÆÚ/Ò©Îï×÷ÓÃ,cell cycle/drug effectsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« θÃÚËØÊÜÌå,gastrin receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ°°×ÖÊSurvivin,Protein SurvivinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ǰÁÐÏÙËáÐÔÁ×Ëáø,prostatic acid phosphataseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µÍλǰÇгýÊõ,Low anterior resectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö±³¦ÏÙ°©,Rectal adenocarcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½áÖ±³¦Ö×Áö/Õï¶Ï,COLORECTAL NEOPLASMS/diagÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±êÖ¾»ùÒò,marker geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍÁÈÀÄ£ÐÍ,soil modelÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« PCRоƬ,PCR ChipÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÔöֳϵÊý,propagation coefficientÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« HepG_2ϸ°û,HepG_2 cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾úÍÉ,bacterial ghostÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃâÒßÇ׺ÍÉ«Æ×,immunoaffinity chromatographyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ˳²¬×¢ÉäÒº,Cisplatin injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« KAI1/CD82µ°°×,KAI1/CD82 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ʳ¹ÜÔçÆÚ°©,early esophageal cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸´·¢×ªÒÆ,Recurrence and metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÓÕÆ­¹ÑºËÜÕËá,Decoy oligonucleotideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« PTENÁ×ËáË®½âø,PTEN phosphohydrolaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÕæºËÔØÌå,Eukaryotic vectorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸Îϸ°û´Ì¼¤Òò×Ó,Hepatic stimulator substanceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °é°©×ÛºÏÕ÷,Paraneoplastic syndromeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûÒÖÖÆ,Cell inhibitionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×éµ°°×ÍÑÒÒõ£»ùø,histone deacetylaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ʳ¹ÜÖ×Áö/Á÷Ðв¡Ñ§,esophageal neoplasms/epidemiologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²»¿ÉÄæÐÔµç»÷´©,irreversible electrical breakdownÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Áܰͻ¯ÁÆ,lymphatic chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¦Â-catenin»ùÒò,¦Â-catenin geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÊÖÊõÇÐÔµ,Surgical marginÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈÈÐݿ˵°°×gp96,Heat shock protein gp96Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈÚºÏϸ°û,Fusion cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ˫Դ°©,concurrent cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûÉìÕ¹,Cell spreadingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑÎËáÂåÀ­Çú¿Ë,nolatrexed dihydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ºÏÓÃÖ¸Êý,combination index(CI)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«